InflaRx N.V. (IFRX) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 13.0% versus a loss of 4.1%. InflaRx N.V. is the larger company by market cap ($229.9 million vs $218.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | TRDA |
|---|---|---|
| Share price | $1.56 | $5.61 |
| Market cap | $229.89M | $218.43M |
| 1-day change | -1.27% | +3.51% |
| YTD return | +54.46% | -45.43% |
| 1-year return | +13.04% | -4.10% |
| 5-year return | -36.84% | — |
| EPS (TTM) | $-0.58 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $16.45 |
| 52-week low | $0.798 | $5.15 |
| Distance from 52-week high | -47.10% | -65.90% |
| Analyst consensus | none | none |
| Avg. price target upside | +391.03% | +238.68% |
| Average volume | 799.42K | 362.82K |
| Shares outstanding | 147.37M | 38.94M |
| Employees | 65 | 152 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed TRDA by 17.1 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Healthcare · Biotechnology · 152 employees
IFRX vs TRDA FAQ
Which is bigger, InflaRx N.V. or Entrada Therapeutics?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $229.89M compared with $218.43M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, IFRX or TRDA?
IFRX returned +13.04% over the past 12 months, compared with -4.10% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.